Monte Rosa announced that it achieved pre-specified research milestones and earned milestone payments under its strategic collaboration and licensing agreement with Roche. In October 2023, Monte Rosa entered into a strategic collaboration and licensing agreement with Roche to discover and develop MGDs against targets in cancer and neurological diseases. Under the terms of the agreement, Monte Rosa received an upfront payment of $50 million and is eligible to receive future preclinical, clinical, commercial, and sales milestone payments that could exceed $2 billion, as well as tiered royalties
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
- These 2 ‘Strong Buy’ Penny Stocks Could Jump at Least 300%, Says Piper Sandler
- Monte Rosa Therapeutics Reports Progress on Drug Development
- Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160